Target intelligence / Profile preview

Norovirus GII.4 capsid protein VP1 (VP1 (GII.4))

Target
VP1 (GII.4)
Molecular classification
Viral structural protein, Capsid protein, Other (forms virus-like particle)
01

Overview

Norovirus GII.4 capsid protein VP1 is the major structural protein forming the outer shell of human norovirus particles. It assembles into icosahedral capsids with T = 3 or T = 4 symmetry, encapsulating the viral RNA genome. The VP1 protein contains an internal N-terminal arm, a shell (S) domain, and a protruding (P) domain. The P domain includes the hypervariable P2 subdomain, which is critical for host cell attachment via glycan/histoblood group antigen binding and determines antigenicity. Sequence variation in the P2 domain drives immune escape and frequent emergence of epidemic variants. VP1 virus-like particles are used in norovirus vaccine development, making it a major therapeutic and diagnostic target[1][2][3][4].

Other names
Major capsid protein VP1 (GII.4)GII.4 VP1Norovirus GII.4 VP1 capsid protein
02

Mechanism of action

Drugs and antibodies under investigation bind the VP1 protein to block cell attachment or induce neutralizing immune responses (vaccine mechanism)[1][3]. Vaccine-induced antibodies recognize conformational epitopes on VP1, particularly the hypervariable P2 domain.

03

Biological functions

Structural assembly of the norovirus capsidCell attachment via glycan bindingAntigenic variation/immune evasionMediates virus entry into host cell
04

Disease associations

Infection (norovirus gastroenteritis)Antigenic variation drives outbreaks and immune escape
05

Safety considerations

High antigenic variability and rapid evolution in VP1 P2 domain complicate vaccine development and may enable immune escape[2][3]Limited cross-protection against various GII.4 variantsNo significant toxicity concerns for VLP-based vaccines derived from VP1
06

Interacting drugs

No approved direct-acting antiviral drugs for norovirus VP1; vaccine candidates target VP1 virus-like particles[1]

1 more in the full profile.

07

Biomarkers

Anti-GII.4 VP1 antibodies (vaccine or infection response)Sequence variations in the P2 domain for antigenic typing and outbreak tracking[3]

Beyond the preview

Go deeper on Norovirus GII.4 capsid protein VP1 (VP1 (GII.4)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norovirus GII.4 capsid protein VP1 (VP1 (GII.4)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call